Next Generation Platforms for Antibody Discovery
Andrew R.M. Bradbury, MB BS, PhD, CSO, Specifica, Inc.
Antibody display libraries have served as a rich source of therapeutic antibodies. However, antibody leads selected from display libraries usually require downstream affinity and developability optimization, extending lead development timelines and costs. Specifica has established a unique antibody discovery display platform based on natural antibody sequences in which subnanomolar antibodies, requiring minimal optimization, are routinely selected.
